Strategic Merger of Adaptimmune and TCR2 Tx; Afami-cel’s BLA Filing Completion on Track for Mid-2023; Progress in ADP-A2M4CD8’s Clinical Development; Adaptimmune Q4 2022 Earnings Call Summary

On Monday, March 6, Adaptimmune held its Q4 and FY 2022 earnings call (press release / presentation) highlighting an agreement with TCR2 Tx for merging into a preeminent cell therapy company focused on treating solid tumors (press release). Additionally, management presented updates from afami-cel’s (autologous MAGE-A4 SPEAR-T) BLA filing in synovial sarcoma and ADP-A2M4CD8’s (autologous MAGE-A4 TCR-T) Ph2 SURPASS-3 trial in ovarian cancer. Below, Celltelligence provides insights on the decision of Adaptimmune to partner with TCR2 Tx while discussing the potential of their combined pipeline in the treatment of solid tumors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.